Immunocore (IMCR) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Immunocore is set to release its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($0.21) per share and revenue of $122.96 million.
• In the previous quarter, Immunocore reported earnings of $0.10 EPS, exceeding estimates, and achieved a 33.6% year-over-year revenue growth.
• Analyst ratings for Immunocore are largely positive, with a consensus price target of $58.89, and institutional investors currently hold 84.50% of the company's stock.

Immunocore (NASDAQ:IMCR - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $122.96 million for the quarter.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.45. The company had revenue of $125.13 million for the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative net margin of 6.48% and a negative return on equity of 5.86%. The business's revenue was up 33.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.49) EPS. On average, analysts expect Immunocore to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immunocore Price Performance

Shares of NASDAQ IMCR traded down $0.73 during trading on Thursday, hitting $32.77. 267,182 shares of the company were exchanged, compared to its average volume of 337,806. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -76.21 and a beta of 0.77. Immunocore has a 1 year low of $23.15 and a 1 year high of $40.52. The firm's fifty day moving average price is $34.19 and its 200 day moving average price is $31.09. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.36 and a quick ratio of 6.31.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on IMCR shares. Mizuho cut their price target on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. Wall Street Zen raised shares of Immunocore from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Needham & Company LLC reissued a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th. HC Wainwright reissued a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research note on Monday, June 2nd. Finally, JPMorgan Chase & Co. cut their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, April 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $58.89.

Hedge Funds Weigh In On Immunocore

A hedge fund recently raised its stake in Immunocore stock. Royal Bank of Canada lifted its position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 45.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,011 shares of the company's stock after acquiring an additional 13,689 shares during the period. Royal Bank of Canada owned about 0.09% of Immunocore worth $1,306,000 at the end of the most recent reporting period. Institutional investors own 84.50% of the company's stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.